Real World Lecanemab Outcome Data at 6 months in an Academic Healthcare System

Abstract

Background: Monoclonal antibodies targeting amyloid‐beta plaques have emerged as a new disease‐modifying drug class that target and remove cerebral amyloid in early‐stage Alzheimer’s disease.

The paper